Conclusion: The sequential screening program mainly based on immunologic fecal occult blood test play an important roles in detecting the early colorectal cancer. But immunologic fecal occult blood test can not distinguish between the innocence and the malignancy, colonoscopy and pathology biopsy are the final screening method. Key Word(s): 1. Colorectal cancer; 2. Fecal occult blood; 3. Immunologic; 4. screening;

Presenting Author: SIEWC STA-9090 datasheet NG Additional Authors: JESSICA CHING, VICTOR CHAN, MARTIN WONG, BING YEE SUEN, HOYEE HIRAI, FRANCISKL CHAN, JAMESYW LAU, JOSEPHJY SUNG Corresponding Author: SIEWC NG Affiliations: CUHK Objective: The role of fecal immunochemical test (FIT) in screening individuals with a positive family history of colorectal cancer (CRC) is not clear. We assessed the diagnostic accuracy of FIT using colonoscopy findings as gold standard in identifying colorectal neoplasms. Methods: We analyzed data from 4,539 asymptomatic subjects aged 50–70 years who had both colonoscopy and FIT at our bowel cancer screening center between 2008 and 2012. We assessed sensitivity of FIT in detecting advanced neoplasms and cancers in subjects with a family history of CRC. Advanced neoplasm was defined as lesions with one of the following: size ≥10 mm, have villous or tubulovillous component, high-grade dysplasia or carcinoma-in-situ. Results: Advanced neoplasms and cancers were found at screening

colonoscopy in 219 (4.8%) and 22 (0.5%) individuals, respectively. The mean age was 57.68 ± standard deviation (SD) 4.86 and 44% were male. 571 subjects (12.6%) had a family history GSK-3 inhibitor of CRC. FIT was positive in 59 (10.3%) subjects. The sensitivity of FIT in detecting adenoma, advanced neoplasm, and cancer in subjects

with a family history of CRC was 9.5% (95% confidence interval [CI], 5.7%–15.3%), 35.1% (95% CI, 20.7%–52.6%), and 25.0% (95% CI, 1.3%–78.1%), respectively. Among FIT negative subjects, adenoma was found in 152 (29.6%), advanced neoplasm in 24 (4.7%) and invasive cancer in 3 (0.6%) individuals who have a family history of CRC. Conclusion: Compared with colonoscopy, FIT is more likely to miss advanced neoplasms MCE or cancer in individuals with a family history of CRC. Key Word(s): 1. FIT; 2. Colorectal cancer; 3. Colonoscopy; 4. Family history; Table 1: Diagnostic performance of FIT Colonoscopy findings FIT positive (N = 52) FIT negative (N = 519) Sensitivety (95% CI) Specificity (95% CI) PPV (95% CI) MPV (95% CI) All neoplasms 27 (13%) 181 (87%) 13.0 (8.9–18.5) 93.1 (89.9–95.4) 51.9 (97.8–65.8) 65.1 (60.8–69.2) Hyperplastic polyps 1 (3%) 32 (97%) 3.0 (0.2–17.5) 90.5 (87.6–92.8) 1.9 (0.1–11.6) 93.8 (91.3–95.7) Non-advanced neoplasm 15 (9%) 153 (91%) 8.9 (5.3–14.6) 90.8 (87.5–93.4) 28.8 (17.5–43.2) 70.5 (66.4–74.4) Advanced neoplasm 11 (31%) 25 (69%) 30.6 (16.9–48.3) 92.3 (89.7–94.4) 21.2 (11.5–35.1) 95.2 (95.9–96.8) Invasive cancer 1 (25%) 3 (75%) 25.0 (1.3–78.1) 91.0 (88.3–93.2) 1.9 (0.1–11.6) 99.4 (98.2–99.